

COPY

PATENT

Examiner:

Our Docket: P-PM 4968.

UCLA Reference: 2001-114-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Braun et al.

Serial No.: 09/976,451

Filed: October 12, 2001

For: METHODS OF DIAGNOSING

AND TREATING CROHN'S

DISEASE USING PSEUDOMONAS

ANTIGENS

ANTIGENS

Group Art Unit: 1645

Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231, on <u>January 15, 2002</u>.

Andrea L. Gashler, Reg. No. 41,029

January 15, 2002

Date of Signature

COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Attention: BOX MISSING PARTS

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-0370.

Respectfully submitted,

Date: <u>January 15, 2002</u>

audica K. Hasuler

Andrea L. Gashler

Registration No.: 41,029 Telephone: (858) 535-9001 Facsimile: (858) 535-8949

Campbell & Flores LLP 4370 La Jolla Village Drive 7th Floor San Diego, California 92122 USPTO CUSTOMER NO. 23601

SERIAL NO. PTO 1449 US Department of ATTY DOCKET NO: 09/976,451 Commerce Patent P-PM 4968 and Trademark APPLICANT: Office Braun et al. GROUP: FILING DATE: INFORMATION DISCLOSURE 1645 STATEMENT BY APPLICANT 10/12/2001

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	6,309,643	10/30/01	Braun et al.			
	6,033,864	03/07/00	Braun et al.			

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANS-L ATION YES/NO
	WO 00/66067	11/09/2000	PCT			
	WO 99/45955	09/19/1999	PCT			
Δ.						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

Abe et al., "Clinical role for a superantigen in <i>Yersinia</i> pseudotuberculosis infection," <u>J. Clin. Invest.</u> 99:1823-1830 (1997).
Ambrose et al., "Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study," <u>Dis. Colon Rectum</u> 28:81-85 (1985).
Aranda et al, "Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4*, CD45RBhigh T cells to SCID recipients," J. Immunol. 158:3464-3473 (1997).

EXAMINER	DATE CONSIDERED

Page 2 of 11

T AFONE	Form PTO 1449		US Department of Commerce Patent	ATTY DOCKET NO: SERIAL NO 09/976,453	
			and Trademark Office	APPLICANT: Braun et al.	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: 10/12/2001	GROUP: 1645	

Blaser et al., "Patients With Active Crohn's Disease Have Elevated Serum Antibodies to Antigens of Seven Enteric Bacterial Pathogens," <u>Gastroenterology</u> 87:888-894 (1984).
Blumberg et al., "Animal models of mucosal inflammation and their relation to human inflammatory bowel disease," <u>Curr.</u> <u>Opin. Immunol.</u> 11:648-656 (1999).
Brandwein et al., "Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora," <u>J. Immunol.</u> 159:44-52 (1997).
Bregenholt et al., "T-cell transfer and cytokine TCR gene deletion models in the study of inflammatory bowel disease," APMIS 105:655-662 (1997).
Brennan et al., "Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus," Microbiology 145:211-20 (1999).
Cachia et al., "The use of synthetic peptides in the design of a consensus sequence vaccine for <i>Pseudomonas aeruginosa</i> ," <u>J. Pept. Res.</u> 52:289-99 (1998).
Callanan et al., "Regulation of the iron uptake genes in Pseudomonas fluorescens M114 by pseudobactin M114:the pbrA sigma factor gene does not mediate the siderophore regulatory response," <u>FEMS Microbiol. Lett.</u> 144:61-66 (1996).
Campbell et al., "Interaction of the receptor binding domains of <i>Pseudomonas aeruginosa</i> pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: implications for synthetic vaccine design," <u>J. Mol. Biol.</u> 267:382-402 (1997).

EXAMINER	DATE CONSIDERED

Page 3 of 11

		rage 5 or 11
Form PTO 1449 US Department of	ATTY DOCKET NO:	SERIAL NO.
Commerce Patent	P-PM 4968	09/976,451
and Trademark Office	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE	FILING DATE:	GROUP:
STATEMENT BY APPLICANT	10/12/2001	1645

Cellier et al., "Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue," Gastroenterol. Clin. Biol. 22:675-678 (1998).
Chen et al., "Recombinant protein composed of <i>Pseudomonas</i> exotoxin A, outer membrane proteins I and F as vaccine against <i>P. aeruginosa</i> infection," <u>Appl. Microbiol.</u> <u>Biotechnol.</u> 52:524-33 (1999).
Chiba et al., "No Mycobacterium paratuberculosis detected in intestinal tissue, including Peyer's patches and lymph follicles, of Crohn's disease," <u>J. Gastroenterology</u> 33:482-487 (1998).
Cho-Chung, "Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment," <u>Pharmacol. Ther.</u> 82:437-449 (1999).
Clarkston et al., "Role of <i>Mycobacterium Paratuberculosis</i> in Crohn's Disease," <u>Dis. Colon Rectum</u> 41:195-199 (1998).
Cocito et al., "Paratuberculosis," <u>Clinical Microbiology</u> <u>Reviews</u> 7:328-345 (1994).
Cong et al., "CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease," J. Exp. Med. 187:855-864 (1998).
Cripps et al., "Vaccine strategies against <i>Pseudomonas</i> aeruginosa infection in the lung," <u>Behring Inst. Mitt.</u> 98:262-268 (1997).
Cryz et al., "Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine," Vaccine 13:449-453 (1995).

EXAMINER	DATE CONSIDERED

Page 4 of 13

A"			Page 4 of 11
FART PTO 1449	US Department of	ATTY DOCKET NO:	SERIAL NO.
	Commerce Patent	P-PM 4968	09/976,451
	and Trademark Office	APPLICANT: Braun et al.	
INFORMATION DI		FILING DATE:	GROUP:
STATEMENT BY A		10/12/2001	1645

Dalwadi et al., "Identification of a novel IBD-Associated microbial agent by representational difference analysis," <u>Gastroenterology</u> 116(4): A696 AGA Abstracts (1999).
Dalwadi et al., "The Crohn's disease-associated bacterial protein, I2, is a novel enteric T cell superantigen" Immunity 15:149-58 (2001).
Del Prete et al., "Detection of <i>Mycobacterium</i> paratuberculosis in stool samples of patients with inflammatory bowel disease by IS900-based PCR and colorimetric detection of amplified DNA," <u>J. Microbiol.</u> Methods 33:105-114 (1998).
Dianda et al., "T cell receptor- $\alpha\beta$ -deficient mice fail to develop colitis in the absence of a microbial environment," Am. J. Pathol. 150:91-97 (1997).
Doring and Dorner, "A multicenter vaccine trial using the <i>Pseudomonas aeruginosa</i> flagella vaccine IMMUNO in patients with cystic fibrosis," <u>Behring Inst. Mitt</u> . 98:338-344 (1997).
El-Zaatari et al., "Characterization of a Specific Mycobacterium paratuberculosis Recombinant Clone Expressing 35,000-Molecular-Weight Antigen and Reactivity with Sera from Animals with Clinical and Subclinical Johne's Disease," Journal of Clinical Microbiology 35:1794-1799 (1997).
Elsaghier et al., "Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease," Clin. Exp. Immunol. 90:503-508 (1992).
Epelman et al., "Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines," Infect. Immun. 68:4811-4814 (2000).

EXAMINER	DATE CONSIDERED

8	Mar si				Page 5 of 11
	FORT	PTO 1449	US Department of Commerce Patent	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
n,		Office	APPLICANT: Braun et al.		
	8	RMATION DI		FILING DATE: 10/12/2001	GROUP: 1645

Fidler et al., "Specific detection of <i>Mycobacterium</i> paratuberculosis DNA associated with granulomatous tissue in Crohn's disease," <u>Gut</u> 35:506-510 (1994).
Finegold and Sutter, "Fecal flora in different populations, with special reference to diet," <u>Am. J. Clin. Nutr.</u> 31:S116-S122 (1978).
Finegold et al., "Fecal microbial flora in Seventh Day Adventist populations and control subjects," <u>Am. J. Clin.</u> Nutr. 30:1781-1792 (1977).
GenBank Accession No.: AF173683.2 - Pseudomonas fluorescens putative transcriptional regulator PfI2 and PbrA-like transcriptional activator gene, complete cds; and unknown genes.
GenBank Accession No.: AF173683.1 - Bacterium I2 unknown gene.
Gilleland et al., "Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of <i>Pseudomonas aeruginosa</i> ," <u>Curr. Microbiol.</u> 31:279-86 (1995).
Gionchetti et al., "Review - antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach," <u>Eur. Rev. Med. Pharmacol. Sci.</u> 3:27-30 (1999).
Graham et al., "DNA hybridization studies of the association of <i>Pseudomonas maltophilia</i> with inflammatory bowel diseases," <u>J. Lab. Clin. Med.</u> 101:940-954 (1983).
Gui et al., "Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics," J. Antimicrob. Chemother. 39:393-400 (1997).

EXAMINER	DATE CONSIDERED

Page 6 of 11

	<u> </u>					Page 6 OL 11
22	FORM ENIVER	PTO	1449		ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
				and Trademark Office	APPLICANT: Braun et al.	
				SCLOSURE PPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

Ichikawa et al., "Interaction of <i>Pseudomonas aeruginosa</i> with epithelial cells: Identification of differentially regulated genes by expression microarray analysis of human cDNAs," Proc.Natl.Acad.Sci.USA 97:9659-9664 (2000).
Jang et al., "Human immune response to a <i>Pseudomonas aeruginosa</i> outer membrane protein vaccine," <u>Vaccine</u> 17:158-68 (1999).
Janowitz et al., "The role of the fecal stream in Crohn's disease: An historical and analytic review," <u>Inflamm. Bowel Dis.</u> 4:29-39 (1998).
Ji et al., "Identification of Critical Staphylococcal Genes Using Conditional Phenotypes Generated by Antisense RNA," Science 293:2266-2269 (2001).
Juliano and Yoo, "Aspects of the transport and delivery of antisense oligonucleotides," Curr.Opin.Mol.Ther.2:297-303 (2000).
Knapp et al., "A recombinant hybrid outer membrane protein for vaccination against <i>Pseudomonas aeruginosa</i> ," <u>Vaccine</u> 17:1663-1666 (1999).
Koukalova et al., "Development of a vaccine for treatment of urinary tract inflammatory diseases," <u>Bratisl. Lek. Listy</u> 100:92-5 (1999)
Lang et al., "Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis," J. Pediatr. 127:711-717 (1995).

EXAMINER	DATE CONSIDERED

Page 7 of 11

Form PTO 1449 US Department of Commerce Patent		ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	and Trademark Office	APPLICANT: Braun et al.	
INFORMATION DI STATEMENT BY A		FILING DATE: 10/12/2001	GROUP: 1645

·	Langholz et al., "Treatment of Crohn's disease with fusidic acid: An antibiotic with immunosuppressive properties similar to cyclosporin," Aliment Pharmacol. Ther. 6:495-502 (1992).
	Lee et al., "Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans," <u>FEMS Immunol. Med. Microbiol.</u> 27:79-85 (2000).
	Lee et al., "Immunization of burn-patients with a <i>Pseudomonas aeruginosa</i> outer membrane protein vaccine elicits antibodies with protective efficacy," <u>Vaccine</u> 18:1952-61 (2000).
	Leoni et al., "Functional analysis of PvdS, an iron starvation sigma factor of <i>Pseudomonas aeruginosa</i> ," <u>J. Bacteriol.</u> 182:1481-1491 (2000).
	Lewin and Hauswirth, "Ribozyme gene therapy: Applications for molecular medicine," <u>Trends. Mol. Med.</u> 7:221-228 (2001).
	Li et al., "The structural basis of T cell activation by superantigens," <u>Annu. Rev. Immunol.</u> 17:435-466 (1999).
	Lister et al., "β-lactamase inhibitor combinations with extended-spectrum penicillins: Factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa," Pharmacotherapy 20:213S-218S (2000).
	Mansouri et al., "Safety and immunogenicity of a <i>Pseudomonas aeruginosa</i> hybrid outer membrane protein F-I vaccine in human volunteers," <u>Infect. Immun.</u> 67:1461-70 (1999).
	Marrack and Kappler, "Subversion of the immune system by pathogens," Cell 76:323-332 (1994).

EXAMINER	DATE CONSIDERED

Page 8 of 11

ξ.		 			1490 0 01 11
1	37	US Department of Commerce Patent	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451	
			and Trademark Office	APPLICANT: Braun et al.	
			SCLOSURE PPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

Martin and Rohodes, "Bacteria and inflammatory bowel disease," Curr. Opin. Infect. Dis. 13:503-509 (2000).
Moss et al., "Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum in long term cultures from Crohn's disease and control tissues," Gut 33:1209-1213 (1992).
Parent and Mitchell, "Cell wall-defective variants of Pseudomonas-like (group Va) bacteria in Crohn's disease," Gastroenterology 75:368-372 (1978).
Parent and Mitchell, "Bacterial variants: Etiologic agent in Crohn's disease?," <u>Gastroenterology</u> 71:365-368 (1976).
Park et al., "General pharmacology of a Pseudomonas vaccine prepared from outer-membrane fractions of <i>Pseudomonas</i> aeruginosa," Arzne-Forsch/Drug Res. 46(II):1001-6 (1996).
Podolsky, "Lessons from genetic models of inflammatory bowel disease," <u>Acta Gastro-Enterol. Belg.</u> 60:163-165 (1997).
Powrie et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in scid Mice Reconstituted with CD45RB ^{hi} CD4 ⁺ T Cells," <u>Immunity</u> 1:553-562 (1994).
Prantera et al., "Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regime," Am. J. Gastroenterol. 89:513-518 (1994).
Prantera et al., "An Antibiotic Regimen for the Treatment of Active Crohn's Disease: A Randomized, controlled Clinical Trial of Metronidazole plus Ciprofloxacin," Am. J. Gastroenterol. 91:328-332 (1996).

EXAMINER	DATE CONSIDERED

Page 9 of 11

			1 age 7 01 11
C	ommerce Patent	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
and Trademark	APPLICANT:		
Office	Braun et al.		
INFORMATION DISC		FILING DATE:	GROUP:
STATEMENT BY APP		10/12/2001	1645

Rawling and Martin, "Epitope mapping of the <i>Pseudomonas</i> aeruginosa major outer membrane porin protein OprF," <u>Infect.</u> <u>Immun.</u> 63:38-42 (1995).
Sanderson et al., " <i>Mycobacterium paratuberculosis</i> DNA in Crohn's disease tissue," <u>Gut</u> 33:890-896 (1992).
Seibold et al., "pANCA Represents a Cross-Reactivity to Enteric Bacterial Antigens," <u>Journal of Clinical Immunology</u> 18:153-160 (1998).
Sendid et al., "Specific antibody response to oligomannosidic epitopes in Crohn's disease," <u>Clin. Diag.</u> <u>Lab. Immunol.</u> 3:219-226 (1996).
Sexton et al., "Transcriptional regulation of the iron-responsive sigma factor gene <i>pbrA</i> ," <u>Mol. Gen. Genet.</u> 250:50-58 (1996).
Sexton et al., "Iron-responsive gene expression in Pseudomonas fluorescens M114: cloning and characterization of a transcription-activating factor, PbrA," Mol. Microbiol. 15:297-306 (1995).
Sheth et al., "Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein," <u>Biomed. Pept. Proteins</u> Nucleic Acids 1:141-8 (1995).
Siegel et al., "Parathyroid hormone stimulates dephosphorylation of the renoredoxin component of the 25-hydroxyvitamin D_3 -1 α -hydroxylase from rat renal cortex," J. Biol. Chem. 261:16998-17003 (1986).
Sonnenberg, "Occupational distribution of inflammatory bowel disease among German employees," <u>Gut</u> 31:1037-1040 (1990).

EXAMINER	DATE CONSIDERED

Page 10 of 11

<u> </u>			Page 10 OL 11
FORM PTO 1449	US Department of Commerce Patent	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
and Trademark	APPLICANT:		
Office	Braun et al.		
INFORMATION DI		FILING DATE:	GROUP:
STATEMENT BY A		10/12/2001	1645

Stanislavsky et al., "Antigenic and Protective Properties of Lipopolysaccharides of R-Forms of some grame-negative bacteria," Zh. Mikrobiol. Epidemiol. Immunobiol. 52-56 (1998).
Stanislavsky and Lam, "Pseudomonas aeruginosa antigens as potential vaccines," FEMS Microbiol. Rev. 21:243-77 (1997).
Stanislavsky et al., "R-form lipopolysaccharides (LPS) of Gram-negative bacteria as possible vaccine antigens," <u>FEMS Immunol. Med. Microbiol.</u> 18:139-45 (1997).
Stover et al., "Complete genome sequence of <i>Pseudomonas</i> aeruginosa PA01, an opportunistic pathogen," <u>Nature</u> 406:959-964 (2000).
Sutton et al., "Identification of a Novel Bacterial Sequence Associated with Crohn's Disease," <u>Gastroenterology</u> 119:23-31 (2000).
Thomas et al., "Controlled trial of antituberculous chemotherapy in Crohn's disease: A five year follow up study," <u>Gut</u> 42:497-500 (1998).
Vannuffel et al., "Occurrence, in Crohn's Disease, of Antibodies Directed against a Species-Specific Recombinant Polypeptide of Mycobacterium paratuberculosis," Clinical and Diagnostic Laboratory Immunology 1:241-243 (1994).
von Specht et al., "Outer membrane proteins of <i>Pseudomonas aeruginosa</i> as vaccine candidates," <u>J. Biotechnol.</u> 44:145-53 (1996).
von Specht, "A new vaccine against <i>P. aeruginosa</i> infections. Based on recombinant <i>P. aeruginosa</i> outer membrane proteins," Zentralbl. Chir. 124:298-302 (1999).

EXAMINER	DATE CONSIDERED

Page 11 of 11

m PTO 1449 US Department of ATTY DOCKET NO: SERIAL NO. 09/976,451 Commerce Patent P-PM 4968 and Trademark APPLICANT: Office Braun et al. GROUP: INFORMATION DISCLOSURE FILING DATE: 1645 STATEMENT BY APPLICANT 10/12/2001

Wang et al., "Overexpression of murine fizzy-related (fzr) increases natural killer cell-mediated cell death and suppresses tumor growth," <u>Blood</u> 96:259-263 (2000).
Wayne et al., "Immunoglobulin A (IgA) and IgG Serum Antibodies to Mycobacterial Antigens in Crohn's Disease Patients and Their Relatives," <u>J. Clin. Microbiology</u> 30:2013-2018 (1992).
Weiner et al., "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Ann. Rev. Immunol. 12:809-837 (1994).
Weiner, "Oral Tolerance: Mobilizing the Gut," <u>Hospital</u> <u>Practice</u> September 15th, pp. 53-58 (1995).
Wilson et al., "Phylogenetic placement of community members of human colonic biota," <u>Clin. Infect. Dis.</u> 25(S2):S114-S116 (1997).
Wilson et al., "Analysis of promoters recognized by PvdS, an extracytoplasmic-function sigma factor protein from Pseudomonas aeruginosa," J. Bacteriol. 183:2151-2155 (2001).
Xiong et al., "The oxygen- and iron-dependent sigma factor pvdS of Pseudomonas aeruginosa is an important virulence factor in experimental infective endocarditis," <u>J. Infect. Dis.</u> 181:1020-1026 (2000).
Yamaguchi et al., "Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin-Surveillance Group," Japanese J. Antibiot. 53:387-408 (1998).

EXAMINER	DATE CONSIDERED